Introduction: Renal medullary carcinoma (RMC) is a rare form of renal cell carcinoma (RCC) that is typically associated with a loss of function in SMARCB1 and diagnosis of sickle cell or other hemoglobinopathy. In rare cases, this disease can be seen in patients without hemoglobinopathy and is classified as "SMARCB1-deficient RMC without hemoglobinopathy" or referred to as "RCC unclassified with medullary phenotype" in some of the literature. Platinum-based cytotoxic chemotherapy is currently the recommended first-line treatment for this rare disease.
Case Presentation: Here we report a 53-year-old male who was diagnosed with metastatic SMARCB1-deficient RMC without hemoglobinopathy after presenting with left flank and abdominal pain. After initiating first-line pembrolizumab and lenvatinib systemic therapy, imaging showed regression at 6 weeks. To date, this patient continues to show a near complete response to this treatment regimen.
Conclusion: To our knowledge, this is the first documented case of SMARCB1-deficient RMC without hemoglobinopathy to receive this treatment regimen and show such a response.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521492 | PMC |
| http://dx.doi.org/10.1159/000540937 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SMARCB1-deficient malignant melanocytic uveal tumours: a new neural crest-derived tumour entity with SMARCB1-related germline predisposition.
J Pathol
March 2025
SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), Institut Curie, Université Paris Cité, Paris, France.
Rhabdoid tumours (RT) are an aggressive malignancy affecting <2-year-old infants, characterised by biallelic loss-of-function alterations in SWI/SNF-related BAF chromatin remodelling complex subunit B1 (SMARCB1) in nearly all cases. Germline SMARCB1 alterations are found in ~30% of patients and define the RT Predisposition Syndrome type 1 (RTPS1). Uveal melanoma (UVM), the most common primary intraocular cancer in adults, does not harbour SMARCB1 alterations.
View Article and Find Full Text PDFInsights into Thyroid and Salivary Gland Cytopathology: Highlights from a 45th European Congress of Cytology Slide Seminar.
Acta Cytol
December 2024
Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal.
Article Synopsis
- Thyroid and salivary gland cytopathology often present diagnostic challenges due to overlapping features and rare conditions, prompting a focused seminar at the 45th European Congress of Cytology to address these issues.
- The seminar showcased complex cases using fine-needle aspiration cytology (FNAC) alongside histopathological and molecular analyses to differentiate between benign and malignant lesions.
- The findings emphasize the necessity of a comprehensive, multidisciplinary diagnostic approach that integrates cytological, clinical, and histopathological data for accurate patient management.
Extraaxial Poorly Differentiated Chordoma: Clinicopathologic and Molecular Genetic Characterization.
Mod Pathol
November 2024
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. Electronic address:
Article Synopsis
- In a study of six EAPDC cases, histological features were similar to axial PDC, showing malignant cell characteristics, and genetic analysis revealed common loss of the SMARCB1 gene.
- Follow-up revealed significant clinical challenges, including local recurrences and metastasis within months of surgery, highlighting the aggressive nature and poor prognosis of these rare tumors.
Tertiary lymphoid structures potentially promote immune checkpoint inhibitor response in SMARCB1-deficient medullary renal cell carcinoma.
NPJ Precis Oncol
November 2024
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
The WHO's classification of renal cell carcinoma (RCC) has identified loss of SMARCB1 as one of the driven mutations. Despite intensive postoperative interventions, the prognosis for SMARCB1-deficient medullary RCC remains poor, indicating insufficiency in current therapy. Herein, we reported the treatment outcomes of five patients with metastatic SMARCB1-deficient medullary RCC and molecular correlates.
View Article and Find Full Text PDFSMARCB1-deficient renal medullary carcinoma with an EML4::ALK fusion gene in a Japanese woman.
Pathol Int
December 2024
Department of Urology, Shinshu University School of Medicine, Matsumoto, Japan.
Renal medullary carcinoma is a rare, high-grade carcinoma arising in the renal medulla, which is usually associated with sickle cell trait, and there are very few documented cases in the Japanese population. We report a case of renal medullary carcinoma, immunohistochemically defined as SMARCB1 deficient, in a 67-year-old Japanese woman without a history of sickle cell trait. Somatic mutation of SMARCB1 and an EML4::ALK fusion gene were identified by comprehensive genomic profiling.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!